1. INBS announces a 1-for-10 reverse stock split effective December 15, 2025. 2. Stock trading resumes on December 16 with adjusted share quantity. 3. Approximately 959,533 shares will remain outstanding post-split. 4. The reverse split aims to enhance stock attractiveness and compliance with listing standards. 5. Proportionate adjustments will be made to equity-based awards and rights.
FAQ
Why Neutral?
While a reverse split can improve perception, it does not directly affect company valuation. Historical examples show mixed results; for instance, some companies see short-term increases while others suffer long-term declines post-split.
How important is it?
The reverse split is significant in indicating management's strategy to uplift stock value. Its successful implementation may instill confidence, affecting market sentiment directionally.
Why Short Term?
The impact will likely manifest quickly post-split as trading resumes. However, sustained effects depend on company performance and market conditions ahead.
Related Companies
Intelligent Bio Solutions Inc. Announces Reverse Stock Split
NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) — Intelligent Bio Solutions Inc. (NASDAQ: INBS), a leader in medical technology providing innovative, non-invasive testing solutions, has announced a 1-for-10 reverse stock split for its common stock. This split will take effect at 11:59 PM (Eastern Time) on December 15, 2025, marking a significant corporate restructuring designed to enhance stock value.
Details of the Reverse Stock Split
On December 16, 2025, trading for Intelligent Bio Solutions' common stock will continue on The Nasdaq Capital Market (Nasdaq) under its existing trading symbol, “INBS,” but on a split-adjusted basis. The new CUSIP number following the split is 36151G709.
The reverse stock split—approved by shareholders during the annual meeting on October 16, 2025—will combine every ten shares of common stock into one share. This adjustment will also extend to equity-based awards and warrant agreements associated with the stock.
- Effective Date: December 15, 2025, at 11:59 PM ET
- Split Ratio: 1-for-10
- Issued Shares Post-Split: Approximately 959,533 shares
- Par Value: Maintained at $0.01 per share
- Authorized Shares: Unchanged at 100 million shares
It is important to note that fractional shares will not be issued; stockholders eligible for fractional shares will instead receive a cash payment.
Impact on Shareholders
The reverse stock split will uniformly affect all stockholders, preserving their percentage interests in Intelligent Bio Solutions, except for those who may be compensated in cash for fractional shares. This strategic move is aimed at repositioning the company for future growth and investment opportunities.
About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc. (NASDAQ: INBS) specializes in cutting-edge medical technology, particularly its Intelligent Fingerprinting Drug Screening System. This solution enhances on-site testing capabilities through fingerprint sweat analysis, allowing for rapid drug detection. The system is hygienic, cost-effective, and designed for use in various sectors, including:
- Construction
- Manufacturing and Engineering
- Transport and Logistics
- Mining
- Drug Treatment Organizations
- Coroners
This innovative technology has the potential to streamline drug testing in safety-critical industries, providing results in under ten minutes.
Forward-Looking Statements
This announcement contains forward-looking statements regarding Intelligent Bio Solutions Inc.'s future operations and performance, as defined by the relevant U.S. securities laws. Such statements involve risks and uncertainties, including the company's ability to commercialize its products and achieve necessary regulatory approvals. Actual results may differ significantly due to various factors.
For further information, please visit: Intelligent Bio Solutions Inc.